Targeting Interleukin-5 in Refractory and Relapsing Churg–Strauss Syndrome
2011-09-06

Letters6 September 2011Targeting Interleukin-5 in Refractory and Relapsing Churg–Strauss SyndromeFrank Moosig, MD, PhD, Wolfgang Ludwig Gross, MD, PhD, Kristina Herrmann, MD, Jan Phillip Bremer, MD, and Bernhard Hellmich, MD, PhDFrank Moosig, MD, PhDFrom University of Lübeck and Clinic Bad Bramstedt, 24576 Bad Bramstedt, Germany, and University of Tübingen and Hospital Plochingen, 73207 Tübingen, Germany., Wolfgang Ludwig Gross, MD, PhDFrom University of Lübeck and Clinic Bad Bramstedt, 24576 Bad Bramstedt, Germany, and University of Tübingen and Hospital Plochingen, 73207 Tübingen, Germany., Kristina Herrmann, MDFrom University of Lübeck and Clinic Bad Bramstedt, 24576 Bad Bramstedt, Germany, and University of Tübingen and Hospital Plochingen, 73207 Tübingen, Germany., Jan Phillip Bremer, MDFrom University of Lübeck and Clinic Bad Bramstedt, 24576 Bad Bramstedt, Germany, and University of Tübingen and Hospital Plochingen, 73207 Tübingen, Germany., and Bernhard Hellmich, MD, PhDFrom University of Lübeck and Clinic Bad Bramstedt, 24576 Bad Bramstedt, Germany, and University of Tübingen and Hospital Plochingen, 73207 Tübingen, Germany.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-155-5-201109060-00026 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This article has been corrected. The original version (PDF) is appended to this article as a supplement.Background: Hypereosinophilia plays a critical role in the pathogenesis of the Churg–Strauss syndrome. Interleukin-5 (IL-5) is the most potent inducer of maturation and activation of eosinophils. We demonstrated elsewhere (1) that IL-5 production is increased in the Churg–Strauss syndrome and that interferon-α therapy, which downregulates IL-5 production, can induce remission of this condition (2). However, long-term results with interferon-α and other biological and conventional drugs, such as cyclophosphamide, have been disappointing.Frequent relapses, the need for long-term medium- to high-dose glucocorticosteroid therapy, and ...References1. Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci. 2005;1051:121-31. [PMID: 16126951] CrossrefMedlineGoogle Scholar2. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med. 1998;129:370-4. [PMID: 9735064] LinkGoogle Scholar3. Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, et al; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358:1215-28. [PMID: 18344568] CrossrefMedlineGoogle Scholar4. Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125:1336-43. [PMID: 20513524] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University of Lübeck and Clinic Bad Bramstedt, 24576 Bad Bramstedt, Germany, and University of Tübingen and Hospital Plochingen, 73207 Tübingen, Germany.Disclosures: This study was financially supported by GSK, and GSK provided the study medication. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoInterferon-α Treatment of Four Patients with the Churg-Strauss Syndrome Efstratios Tatsis , Armin Schnabel , and Wolfgang L. Gross Correction: Targeting Interleukin-5 in Refactory and Releasing Churg-Strauss Syndrome Metrics Cited byEGPA Phenotyping: Not Only ANCA, but Also EosinophilsA Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with PolyangiitisManagement of Severe Asthma in Eosinophilic Granulomatosis with Polyangiitis with Interleukin-5-Targeted Therapies: Current Status and Report of Two CasesEosinophile Granulomatose mit PolyangiitisPerspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With PolyangiitisFrom DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseasesMepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational StudyPulmonale Manifestationen von VaskulitidenResponse to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitisEosinophilic granulomatosis with polyangiitisMepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case seriesNovel Targets for Drug Use in Eosinophilic Granulomatosis With PolyangiitisSteroid alternatives for managing eosinophilic lung diseasesLessons learned from targeting eosinophils in human diseaseMepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumabKortisonfreie Rheumatologie – VaskulitidenEosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological TherapiesRituximab for eosinophilic granulomatosis with polyangiitis: a systematic review of observational studiesConjunctival Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) in a Young Adult Male With Persistent PtosisSuccessful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumabClinical Features of Patients with Active Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with MepolizumabCardiac Involvement in Eosinophilic Granulomatosis With Polyangiitis: A Retrospective Study in the Chinese PopulationParticularités de la granulomatose éosinophilique avec polyangéite (ex-syndrome de Churg-Strauss)French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides)Multiple hepatic aneurysms and dry gangrene of fingertips in eosinophilic granulomatosis with polyangiitis: a case reportRole of Cytokines in EGPA and the Possibility of Treatment with an Anti-IL-5 AntibodyTreatment of Vasculitis: Beyond the BasicsBiologics for the Treatment of Allergic Conditions: Eosinophil DisordersTargeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic ConditionsANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission induction and maintenanceTreatment of systemic necrotizing vasculitides: The 40-year experience of the French Vasculitis Study GroupUpdates for the treatment of EGPALung involvement in ANCA-associated vasculitisAnti-cytokine targeted therapies for ANCA-associated vasculitisMarked neurological and immunological improvement in refractory eosinophilic granulomatous polyangiitis after treatment with mepolizumab, an anti‐interleukin‐5 antibody: A case reportINTERLEUKIN-5 IS A NEW TARGET IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITISEosinophilic Granulomatosis with Polyangiitis: The Beginning of a New EraEosinophilic granulomatosis with polyangiitis: understanding the disease and its managementEosinophilic granulomatosis with polyangiitis treated with mepolizumab at a dose of 100 mg/monthGranulomatosis eosinofílica con poliangeítis tratada con mepolizumab en dosis de 100 mg/mesRetiform purpura: Workup and therapeutic considerations in select conditionsEosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the diseaseTreatment of ANCA-Associated VasculitidesEosinophilic VasculitisEosinophilic lung diseaseGranulomatose éosinophilique avec polyangéite : pathogénie et conséquences thérapeutiquesOral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitisLow-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With PolyangiitisEosinphilic granulomatosis with polyangiitisTreatment of systemic necrotizing vasculitides: recent advances and important clinical considerationsAdvances in Therapies and Imaging for Systemic VasculitisMepolizumab for the treatment of eosinophilic granulomatosis with polyangiitisEvaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitisAktuelle Therapie der eosinophilen Granulomatose mit Polyangiitis (Churg-Strauss-Syndrom)Targeted immunotherapy strategies in ANCA-associated vasculitisSafety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with PolyangiitisStratégies d'immunothérapie ciblée au cours des vascularites associées aux ANCAEosinophilic Granulomatosis with Polyangiitis: Experiences in Korean PatientsEosinophilia and Kidney Disease: More than Just an Incidental Finding?Eosinophile Granulomatose und Polyangiitis – Diagnostik und TherapieLong-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic SyndromeIgG4-related disease: association between chronic rhino-sinusitis and systemic symptomsTreatment of Eosinophilic Granulomatosis with Polyangiitis: A ReviewAnti-Interleukin-5-Therapie und eosinophile Granulomatose mit PolyangiitisEosinophilic Granulomatosis With Polyangiitis: Newer TherapiesTargeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than AsthmaCutaneous Manifestations of Reactions to BiologicsConventional and biological immunosuppressants in vasculitisS1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten VaskulitidenCurrent and Future Treatment Options for Eosinophilic Granulomatosis With PolyangiitisTherapeutic Management of Pediatric Antineutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisBiologic Agents for the Treatment of Hypereosinophilic SyndromesRenal Vasculitis in ChildhoodScheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitisTargeting Interleukin-5 or Interleukin-5Rα: Safety ConsiderationsPerspectives de traitement par biomédicaments dans la granulomatose éosinophilique avec polyangéite (Churg-Strauss)Mécanismes de la granulomatose éosinophilique avec polyangéite (Churg-Strauss)Update on systemic vasculitidesInterferon-α for Induction and Maintenance of Remission in Eosinophilic Granulomatosis with Polyangiitis: A Single-center Retrospective Observational Cohort StudyTargeting Eosinophils in Eosinophilic Granulomatosis with PolyangiitisMepolizumab or Placebo for Eosinophilic Granulomatosis with PolyangiitisTwo cases of atypical hemolytic uremic syndrome (aHUS) and eosinophilic granulomatosis with polyangiitis (EGPA): a possible relationshipBiologic Therapies for Immunoglobulin E–mediated Food Allergy and Eosinophilic EsophagitisEosinophils in Autoimmune DiseasesThe Role of Omalizumab in Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg‐Strauss): Comment on the Article by Jachiet et alAktuelle Leitlinien zu ANCA-assoziierten VaskulitidenNecrotizing eosinophilic granulomatous lymphadenitis with ring- and C-shaped granulomas—an underrecognized specific manifestation of nodal Churg-Strauss syndromeClinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learnANCA-Associated VasculitisAnti-neutrophil Cytoplasmic Antibody–Associated VasculitisEosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome) as a differential diagnosis of hypereosinophilic syndromesChurg-Strauss Syndrome or Eosinophilic Granulomatosis with PolyangiitisMepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potentialOptimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen PatientsEosinophilic Lung DiseasesManagement of Small Vessel VasculitidesBiological Modulators in Eosinophilic DiseasesInterleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disordersOmalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up studyPulmonale Manifestationen von VaskulitidenAntineutrophil Cytoplasmic Antibody Associated VasculitisEosinophilic Lung DiseasesTherapeutic immunomodulation in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)Immunomodulation thérapeutique dans la granulomatose éosinophilique avec polyangéite (Churg-Strauss)Current approaches to diagnosing and treating eosinophilic granulomatosis with polyangiitis: The 2015 international guidelinesVaskulitiden im KindesalterEosinophilic granulomatosis with polyangiitis (formerly Churg–Strauss syndrome): where are we now?Vasculitic NeuropathiesEosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and managementEosinophilia in Rheumatologic/Vascular DisordersBiological drugs in ANCA-associated vasculitisEAACI IG Biologicals task force paper on the use of biologic agents in allergic disordersUpdate on the treatment of ANCA associated vasculitisBiologics in vasculitides: Where do we stand, where do we go from now?Pharmacological approach to treating eosinophilic granulomatosis with polyangiitis (Churg–Strauss)Churg–Strauss syndromeSerum Biomarkers in Patients with Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)Biologic Therapies Targeting Eosinophils: Current Status and Future ProspectsCurrent Landscape of Antineutrophil Cytoplasmic Antibody-Associated VasculitisCurrent Therapies for ANCA-Associated VasculitisNovel Targeted Therapies for Eosinophil-Associated Diseases and AllergyEosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): A Clinical and Therapeutic ApproachPulmonary VasculitisANCA-assoziierte VaskulitidenAntineutrophil cytoplasmic antibody–associated vasculitisChurg-Strauss AngiitisEosinophilic Granulomatosis with Polyangiitis: An OverviewVascularites associées aux anticorps anticytoplasme des polynucléaires neutrophiles : nouveaux traitementsSíndromes eosinofílicos pulmonaresState of the Art in the Treatment of Systemic VasculitidesKey advances in the clinical approach to ANCA-associated vasculitisImpact of rituximab trials on the treatment of ANCA-associated vasculitisThe novel approaches to the treatment of eosinophilic granulomatosis with polyangitisBiological therapy for systemic vasculitis: A systematic reviewIntravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentumVaskulitidenPulmonary VasculitisPulmonary VasculitisEmerging therapies in antineutrophil cytoplasm antibody-associated vasculitisEosinophilic granulomatosis with polyangiitis (Churg–Strauss)Anti-IL5 therapy for asthma and beyondNew-generation therapy for ANCA-associated vasculitisCorrection: Targeting Interleukin-5 in Refactory and Releasing Churg-Strauss SyndromeTherapeutic immunomodulation in systemic vasculitis: Taking stockANCA ("anti-neutrophil cytoplasm antibody")-assoziierte VaskulitidenA vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg–Strauss, EGPA): monocentric experiences in 150 patientsImmunomodulation thérapeutique au cours des vascularites systémiques : état des lieuxControl of inflammatory heart disease by CD4 + T cellsHypereosinophile SyndromeIgG4-related Disease: 2013 UpdateL6. Eosinophilic granulomatosis with polyangiitis: Future therapiesA fatal attraction: eosinophils and the heartEosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the artTreatment of ANCA-associated vasculitides (AAV)Interferon-α induced remission in three patients with eosinophilic granulomatosis and polyangiitis. A case studyChurg–Strauss Syndrome: An evolving paradigmUpdate Churg-Strauss-SyndromEosinophilic Lung DiseasesLa granulomatose éosinophilique avec polyangéite (syndrome de Churg et Strauss)Novel targeted therapies for eosinophilic disorders 6 September 2011Volume 155, Issue 5Page: 341-343KeywordsAdverse eventsCyclophosphamideDrugsEosinophilsGlucocorticoid therapyImmunosuppressivesMethotrexatePathogenesisSafetyVasculitis ePublished: 6 September 2011 Issue Published: 6 September 2011 Copyright & PermissionsCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...